Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Matteo Brioschi"'
Autor:
Julie K. Fierle, Johan Abram-Saliba, Vasileios Atsaves, Matteo Brioschi, Mariastella de Tiani, Patrick Reichenbach, Melita Irving, George Coukos, Steven M. Dunn
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Anti-tumor therapies that seek to exploit and redirect the cytotoxic killing and effector potential of autologous or syngeneic T cells have shown extraordinary promise and efficacy in certain clinical settings. Such cells, when engineered to
Externí odkaz:
https://doaj.org/article/5272d46530e645cbb33e011fe7c50336
Autor:
Alessandro Beghini, Francesca Corlazzoli, Luca Del Giacco, Matteo Re, Francesca Lazzaroni, Matteo Brioschi, Giorgio Valentini, Fulvia Ferrazzi, Anna Ghilardi, Marco Righi, Mauro Turrini, Marco Mignardi, Clara Cesana, Vincenzo Bronte, Mats Nilsson, Enrica Morra, Roberto Cairoli
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 12, Pp 1236-1248 (2012)
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by two molecularly distinct self-renewing leukemic stem cell (LSC) populations most closely related to normal progenitors and organized as a hierarchy. A requir
Externí odkaz:
https://doaj.org/article/4e813f2d2b8d4ab8b429a079662bc8a2
Autor:
Matteo Brioschi, John Fischer, Roberto Cairoli, Stefano Rossetti, Laura Pezzetti, Michele Nichelatti, Mauro Turrini, Francesca Corlazzoli, Barbara Scarpati, Enrica Morra, Nicoletta Sacchi, Alessandro Beghini
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 11, Pp 866-876 (2010)
Core-binding factor leukemia (CBFL) is a subgroup of acutemyeloid leukemia (AML) characterized by genetic mutations involving the subunits of the core-binding factor (CBF). The leukemogenesis model for CBFL posits that one, or more, gene mutations in
Externí odkaz:
https://doaj.org/article/0593b60bb3cf453fa4a7f1e0086d1d43
Autor:
Laureline Wetterwald, George Coukos, Vasileios Atsaves, Tatiana V. Petrova, Mariastella de Tiani, Julie K. Fierle, Steven M. Dunn, Johan Abram-Saliba, Matteo Brioschi
Publikováno v:
Cell Reports Medicine
Cell reports. Medicine, vol. 2, no. 8, pp. 100362
Cell reports. Medicine, vol. 2, no. 8, pp. 100362
Summary Tumor endothelial marker 1 (TEM1) is an emerging cancer target with a unique dual expression profile. First, TEM1 is expressed in the stroma and neo-vasculature of many human carcinomas but is largely absent from healthy adult tissues. Second
Autor:
Johan Abram-Saliba, George Coukos, Mariastella deTiani, Julie K. Fierle, Steven M. Dunn, Matteo Brioschi
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Scientific reports, vol. 9, no. 1, pp. 12815
Scientific Reports
Scientific reports, vol. 9, no. 1, pp. 12815
Scientific Reports
An early bottleneck in the rapid isolation of new antibody fragment binders using in vitro library approaches is the inertia encountered in acquiring and preparing soluble antigen fragments. In this report, we describe a simple, yet powerful strategy
Autor:
Domenica Ceraulo, Michele Ghidini, Roberto Nicoletti, Matteo Brioschi, Stefano Cereda, Alessia Rognone, Clara Fugazza, Michele Reni, Eugenio Villa
Publikováno v:
Chemotherapy. 57:156-161
Background: At the time of upfront treatment failure, over half of the patients with advanced pancreatic cancer are candidates for further treatment. Methods: Patients with metastatic gemcitabine-resistant pancreatic cancer were treated with mitomyci
Autor:
Alessandro Beghini, Nicoletta Sacchi, Enrica Morra, Michele Nichelatti, Laura Pezzetti, Barbara Scarpati, Francesca Corlazzoli, Roberto Cairoli, Stefano Rossetti, John Fischer, Mauro Turrini, Matteo Brioschi
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 11, Pp 866-876 (2010)
Core-binding factor leukemia (CBFL) is a subgroup of acutemyeloid leukemia (AML) characterized by genetic mutations involving the subunits of the core-binding factor (CBF). The leukemogenesis model for CBFL posits that one, or more, gene mutations in
Autor:
Elke Guenther, Lia Scarabottolo, Matteo Brioschi, Sara Tremolada, Loredana Redaelli, Christina Kuhn, Giovanna Maresca, Dietmar Hess
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 81:376-377
Autor:
Anna Ghilardi, Matteo Re, Luca Del Giacco, Francesca Corlazzoli, Clara Cesana, Vincenzo Bronte, Marco Righi, Mats Nilsson, Fulvia Ferrazzi, Marco Mignardi, Mauro Turrini, Giorgio Valentini, Francesca Lazzaroni, Matteo Brioschi, Roberto Cairoli, Enrica Morra, Alessandro Beghini
Publikováno v:
Europe PubMed Central
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 12, Pp 1236-1248 (2012)
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 12, Pp 1236-1248 (2012)
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by two molecularly distinct self-renewing leukemic stem cell (LSC) populations most closely related to normal progenitors and organized as a hierarchy. A requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d5c95c96480ac3d5213207f084c72e
https://hdl.handle.net/10281/408813
https://hdl.handle.net/10281/408813
Autor:
Stefano, Cereda, Michele, Reni, Alessia, Rognone, Michele, Ghidini, Carmen, Belli, Simona, Longoni, Clara, Fugazza, Matteo, Brioschi, Roberto, Nicoletti, Gianpaolo, Balzano, Paolo, Passoni, Eugenio, Villa
Publikováno v:
Anticancer research. 30(11)
More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they experience upfront treatment failure.Patients with gemcitabine-resistant PA, age76 years and Karnofski performance status (KPS)50 were treat